We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04172441
Recruitment Status : Completed
First Posted : November 21, 2019
Last Update Posted : October 3, 2022
Sponsor:
Information provided by (Responsible Party):
Zealand Pharma

Brief Summary:
The objective of the trial is to evaluate the efficacy of dasiglucagon in reducing glucose requirements in children with persistent congenital hyperinsulinism (CHI) requiring continuous intravenous (IV) glucose administration to prevent/manage hypoglycemia.

Condition or disease Intervention/treatment Phase
Congenital Hyperinsulinism Drug: dasiglucagon Drug: Placebo Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism
Actual Study Start Date : June 22, 2020
Actual Primary Completion Date : March 7, 2022
Actual Study Completion Date : March 7, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: dasiglucagon first then placebo
48 hours of dasiglucagon sc infusion starting at 10 µg/hr with crossover to 48 hours placebo sc infusion (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
Drug: dasiglucagon
Glucagon analog
Other Name: ZP4207

Drug: Placebo
Placebo for dasiglucagon

Experimental: placebo first then dasiglucagon
48 hours of placebo sc infusion with crossover to 48 hours dasiglucagon sc infusion starting at 10 µg/hr (part 1) followed by 21 days of dasiglucagon sc infusion (part 2).
Drug: dasiglucagon
Glucagon analog
Other Name: ZP4207

Drug: Placebo
Placebo for dasiglucagon




Primary Outcome Measures :
  1. Mean intravenous glucose infusion rate [ Time Frame: 36-48 hours after initiation of trial drug ]
    Mean intravenous glucose infusion rate in the last 12 hours of each treatment period during the crossover part of the trial (dasiglucagon or placebo administration)


Secondary Outcome Measures :
  1. Carbohydrates administered [ Time Frame: 0-48 hours after initiation of trial drug ]
    Total amount (g) of carbohydrates administered during the crossover part of the trial (dasiglucagon or placebo administration) per day

  2. Carbohydrates administered [ Time Frame: 0-48 hours after initiation of trial drug ]
    Mean intravenous glucose infusion rate for each 48-hour treatment period during the crossover part of the trial (dasiglucagon or placebo administration)

  3. Carbohydrates administered [ Time Frame: 36-48 hours after initiation of trial drug ]
    Mean intravenous glucose infusion rate below 10 mg/kg/min in the last 12 hours of each treatment period during the crossover part of the trial (yes/no) (dasiglucagon or placebo administration)

  4. Time to complete weaning off intravenous glucose [ Time Frame: Day 5-25 ]
    Time to complete weaning off intravenous glucose administration during part 2

  5. Hypoglycemia event rate in part 2 [ Time Frame: Day 5-25 ]
    Hypoglycemia event rate, defined as number of hypoglycemic events (PG <70 mg/dL or 3.9 mmol/L), as detected by self-monitored plasma glucose

  6. Clinically significant hypoglycemia events in part 2 [ Time Frame: Day 5-25 ]
    Clinically significant hypoglycemia event rate, defined as number of events <54 mg/dL (3.0 mmol/L), as detected by self-monitored plasma glucose

  7. Time to actual hospital discharge [ Time Frame: Day 5-25 ]
    Time (days) from start of part 2 until the patient is discharged from the hospital

  8. Time to pancreatic surgery [ Time Frame: Day 5-25 ]
    Time (days) to pancreatic surgery (sub-total or total pancreatectomy)

  9. Carbohydrates administered [ Time Frame: Day 5-25 ]
    Total amount (g) of carbohydrates administered (regardless of the route) per day

  10. Carbohydrates administered intravenously [ Time Frame: Day 5-25 ]
    Amount (g) of carbohydrates administered via IV glucose infusion or bolus (not as part of total parental nutrition)

  11. Carbohydrates administered parenterally [ Time Frame: Day 5-25 ]
    Amount (g) of carbohydrates administered as part of total parenteral nutrition

  12. Carbohydrates administered orally [ Time Frame: Day 5-25 ]
    Amount (g) of carbohydrates administered via oral route

  13. Carbohydrates administered via gastric feed [ Time Frame: Day 5-25 ]
    Amount (g) of carbohydrates administered via nasogastric tube or gastrostomy

  14. Time in range in part 2 [ Time Frame: Day 5-25 ]
    Percent time in range 70-180 mg/dL (3.9-10.0 mmol/L) as measured by continuous glucose monitoring

  15. Time in hypoglycemia in part 2 [ Time Frame: Day 5-25 ]
    Percent time in hypoglycemia (<70 mg/dL or 3.9 mmol/L) as measured by continuous glucose monitoring

  16. Time in clinically significant hypoglycemia in part 2 [ Time Frame: Day 5-25 ]
    Percent time in clinically significant hypoglycemia (<54 mg/dL or 3.0 mmol/L) as measured by continuous glucose monitoring

  17. Hypoglycemia episodes in part 2 [ Time Frame: Day 5-25 ]
    Rate of hypoglycemia episodes, defined as number of episodes <70 mg/dL (3.9 mmol/L) for 15 min or more, as measured by continuous glucose monitoring

  18. Clinically significant hypoglycemia episodes in part 2 [ Time Frame: Day 5-25 ]
    Rate of clinically significant hypoglycemia episodes, defined as number of episodes <54 mg/dL (3.0 mmol/L) for 15 min or more, as measured by continuous glucose monitoring

  19. Extent of hypoglycemia in part 2 [ Time Frame: Day 5-25 ]
    Extent of hypoglycemia (area over the glucose curve [AOCglucose] below 70 mg/dL [3.9 mmol/L]) as measured by continuous glucose monitoring

  20. Extent of clinically significant hypoglycemia in part 2 [ Time Frame: Day 5-25 ]
    Extent of clinically significant hypoglycemia (area over the glucose curve [AOCglucose] below 54 mg/dL [3.0 mmol/L]) as measured by continuous glucose monitoring

  21. Time in hyperglycemia in part 2 [ Time Frame: Day 5-25 ]
    Percent time in hyperglycemia (>180 mg/dL or 10.0 mmol/L), as measured by continuous glucose monitoring



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Days to 364 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CHI diagnosis established based on the following:

    1. Hyperinsulinemia: plasma insulin above the limit of detection of the assay documented during an event of hypoglycemia, and/or
    2. Hypofattyacidemia: plasma free fatty acid <1.7 mmol/L, and/or
    3. Hypoketonemia: Beta-hydroxybutyrate <1.8 mmol/L, and/or
    4. Glycemic response: an increase in PG of >30 mg/dL (1.7 mmol/L) after 1 mg IV or intramuscular (IM) glucagon administration
  • Male or female, age ≥7 days and <12 months at screening
  • Body weight of ≥2.0 kg (4.4 lbs.)
  • Continuous IV glucose requirement to prevent hypoglycemia

Exclusion Criteria:

  • Is suspected of having a transient form of CHI (e.g., transient hyperinsulinism due to maternal diabetes or perinatal stress)
  • Was born preterm below 34 weeks of gestational age
  • Presence of hypertension or hypotension, including circulatory instability requiring supportive medication or presence of pheochromocytoma
  • Known or suspected presence of severe brain damage
  • Evidence of metabolic, endocrine, or syndromic causes of hypoglycemia not due to hyperinsulinism
  • Use of systemic corticosteroids, e.g., hydrocortisone >20 mg/m2 body surface area or equivalent within 5 days before screening
  • Prior use of lanreotide, sirolimus (mechanistic target of rapamycin [mTOR] inhibitors), anti inflammatory biological agents, or other immune modulating agents. Prior use of octreotide is allowed after a minimum of 48 hour washout before randomization.
  • Any clinically significant abnormality identified on echocardiogram that in the opinion of the investigator would affect the subject's ability to participate in the trial
  • Any recognized clotting or bleeding disorder
  • The use of prescription or non-prescription medications known to cause QT prolongation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04172441


Locations
Layout table for location information
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Cook Children's Medical Center
Fort Worth, Texas, United States, 76104
Germany
University Children's Hospital
Düsseldorf, Germany, 40225
University Hospital, Magdeburg
Magdeburg, Germany, 39120
Israel
Hadassah Medical Center
Jerusalem, Israel, 9765422
United Kingdom
Manchester University NHS Foundation Trust
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Zealand Pharma
Investigators
Layout table for investigator information
Study Director: Jelena Ivkovic, MD Zealand Pharma
Layout table for additonal information
Responsible Party: Zealand Pharma
ClinicalTrials.gov Identifier: NCT04172441    
Other Study ID Numbers: ZP4207-17103
2017-004545-24 ( EudraCT Number )
First Posted: November 21, 2019    Key Record Dates
Last Update Posted: October 3, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Congenital Hyperinsulinism
Nesidioblastosis
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Pancreatic Diseases
Digestive System Diseases
Infant, Newborn, Diseases
Hypoglycemia